AGP Executive Report

Rett syndrome drug push: The EMA’s CHMP has issued a positive opinion for Neuren/Acadia’s DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and children aged 5+, moving the case to a European Commission decision. Cancer care update: The European Commission approved Merck’s KEYTRUDA + Padcev combo for resectable muscle-invasive bladder cancer patients who can’t receive cisplatin, based on KEYNOTE-905/EV-303 results. Breast cancer option: Gilead’s Trodelvy (sacituzumab govitecan) won EU marketing authorisation as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in eligible adults. Cross-border healthcare basics: A guide explains how cross-border healthcare works across Europe—who can use it, what costs are covered, and when prior authorisation is needed. Travel and access rules: A Blue Badge travel guide notes reciprocal parking arrangements that can apply in Liechtenstein and other countries. Border delays: EU’s Entry/Exit System is causing major airport queues, with some travellers facing delays of up to 4–6 hours. Public health and safety: Record heat is forcing school closures and shortened days in parts of Europe, as classrooms struggle without cooling.

Rett syndrome breakthrough: Neuren Pharmaceuticals’ DAYBU (trofinetide) won a positive CHMP recommendation after a re-examination, moving to a European Commission decision; if approved, it would be the first EU treatment for neurobehavioral symptoms of Rett syndrome in adults and children aged five and up. Bladder cancer care upgrade: Merck (Keytruda) plus Padcev (enfortumab vedotin) received European Commission approval as a perioperative option for adults with resectable muscle-invasive bladder cancer who can’t get cisplatin, with trial results showing major improvements in event-free and overall survival. Breast cancer option expands: Gilead’s Trodelvy (sacituzumab govitecan) gained EU marketing authorization as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 therapy. Cross-border healthcare basics: A guide explains how European cross-border healthcare works, including who can use it, what costs are covered, and when prior authorisation is needed. Travel health & access: The EU’s Entry/Exit System is causing airport delays of up to 6 hours, while a Blue Badge travel guide notes reciprocal parking arrangements that include Liechtenstein. Local relevance for Liechtenstein residents: EU rules on banned meat products returning from the EU to Great Britain also list Liechtenstein among included countries in some travel-related priority groups.

Rett syndrome breakthrough: The EU’s CHMP has issued a positive opinion for Neuren Pharmaceuticals’ DAYBU (trofinetide), recommending marketing authorization for neurobehavioral symptoms of Rett syndrome in adults and children aged five and up—now awaiting a final European Commission decision. Bladder cancer options expand: The European Commission approved Merck/MSD’s Keytruda plus Padcev perioperative regimen for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with trial results showing major improvements in event-free and overall survival. Breast cancer advance: Gilead’s Trodelvy (sacituzumab govitecan) won EU marketing authorization as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 therapy. Cross-border care made clearer: A guide explains how cross-border healthcare works across Europe, including when prior authorization is needed and what costs may be covered. Travel health & safety: UK guidance warns travellers returning from the EU that bringing certain meat and dairy products is illegal and can lead to confiscation and fines. Heat and schools: Record European heat is forcing school closures or shortened days, with limited cooling in many classrooms.

EU Sanctions & Security: The European Commission is pushing a Schengen-wide entry ban on Russian combatants tied to fighting in Ukraine, with Estonia warning that hundreds of thousands of Russians have served and that ex-soldiers may be linked to violence at home. Cross-Border Care: A practical guide explains how healthcare rights work when you’re treated abroad in Europe—what’s covered, when prior approval is needed, and how costs are handled. Rett Syndrome Drug Move: Neuren Pharmaceuticals’ DAYBU (trofinetide) cleared a major hurdle in Europe after a positive CHMP opinion, recommending EU marketing authorization for neurobehavioral symptoms of Rett syndrome. Cancer Treatment Updates: The EU also approved Trodelvy for first-line metastatic triple-negative breast cancer in patients not eligible for PD-(L)1 therapy, and approved Keytruda plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. Travel Health & Safety: UK airport warnings highlight rules on returning from the EU with banned meat and dairy products to prevent animal disease spread. Public Health Data: A new map shows where safe drinking water is still out of reach, with billions lacking safely managed services.

Cross-Border Care in Europe: A new explainer breaks down when patients can get treatment abroad, what costs may be covered, when prior authorisation is needed, and how to claim—especially relevant for planned care, urgent needs while travelling, and prescriptions filled across borders. Rett Syndrome Drug Progress: Neuren’s DAYBU (trofinetide) cleared a major step in Europe after a positive CHMP opinion following re-examination, moving to a European Commission decision; if approved, it would be the first EU option for neurobehavioral symptoms of Rett syndrome. Cancer Treatment Updates (Bladder & Breast): The European Commission approved KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer in a perioperative plan, and also authorised Trodelvy for first-line metastatic triple-negative breast cancer for patients not suitable for PD-(L)1 inhibitors. Travel & Disability Practicalities: Guidance highlights that Blue Badge holders may have reciprocal parking access in Liechtenstein and other countries. Public Health & Safety: A global map shows where safe drinking water is still out of reach, underscoring ongoing infrastructure gaps that affect health.

Rett syndrome breakthrough: Neuren Pharmaceuticals’ DAYBU (trofinetide) has cleared a major European hurdle after the EMA’s CHMP issued a positive opinion, recommending EU marketing authorization for treating the neurobehavioral symptoms of Rett syndrome in adults and children aged five and up—final approval is now expected from the European Commission, and the company’s partner Acadia says the recommendation is backed by the Phase 3 LAVENDER study. Cancer care in the EU: The European Commission also approved Merck/MSD’s perioperative KEYTRUDA plus Padcev regimen for cisplatin-ineligible muscle-invasive bladder cancer, and Gilead’s Trodelvy for first-line metastatic triple-negative breast cancer in patients not eligible for PD-(L)1 inhibitors. Everyday health access: UK guidance notes Blue Badge holders can use their badge in Liechtenstein (plus Norway and Switzerland) under reciprocal parking arrangements when travelling. Public health data: A new global map highlights that safe drinking water remains out of reach for billions, with major gaps persisting even where access is near-universal elsewhere.

Rett syndrome breakthrough: The EU’s CHMP has reversed course and issued a positive opinion for Neuren’s DAYBU (trofinetide), recommending marketing authorisation for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older—if the European Commission follows through, it would be the first EU-approved therapy for this indication, with Acadia leading commercialisation. Cancer care advances: The European Commission also approved Gilead’s Trodelvy as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 inhibitors, and approved Merck/MSD’s Keytruda plus Padcev perioperatively for cisplatin-ineligible muscle-invasive bladder cancer, aiming to reduce recurrence and death risk. Public health basics: A new global map highlights that more than 2 billion people still lack safely managed drinking water, showing big gaps even where access is near-universal. Heat and health: Europe’s heatwave is forcing schools to close or shorten days due to limited cooling in classrooms, raising concerns for child safety.

Safe Water Access: A new global map highlights that more than 2 billion people still lack safely managed drinking water at home, with access near-universal in many wealthy countries but below 20% in several low-income regions—an urgent reminder that clean-water infrastructure remains uneven. Rett Syndrome Treatment in Europe: The EU’s CHMP has issued a positive opinion for DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in patients aged 5+, potentially making it the first EU-approved therapy for this indication. Bladder Cancer Care Upgrade: The European Commission approved Keytruda plus Padcev as a perioperative regimen for cisplatin-ineligible adults with resectable muscle-invasive bladder cancer, based on KEYNOTE-905 results showing major improvements in event-free survival and pathologic complete response. Breast Cancer Option Expands: Trodelvy (sacituzumab govitecan) also received EU approval as first-line monotherapy for certain patients with metastatic triple-negative breast cancer who can’t use PD-1/PD-L1 inhibitors. Heat and Schools: Across Europe, record heat is forcing schools to close or shorten days, with limited cooling in many classrooms raising health risks for children.

Rett syndrome treatment: Acadia’s DAYBU® (trofinetide) won a positive CHMP opinion in the EU for neurobehavioral symptoms in adults and children aged five and up—next step is an EC marketing authorization, with support from the Phase 3 LAVENDER study. Bladder cancer care: Merck/MSD’s KEYTRUDA + Padcev combo (pembrolizumab + enfortumab vedotin) secured EU approval as perioperative treatment for resectable muscle-invasive bladder cancer in adults who can’t receive cisplatin, based on KEYNOTE-905/EV-303 results. Breast cancer option: Gilead’s Trodelvy® (sacituzumab govitecan) gained EC approval in the EU as first-line monotherapy for unresectable or metastatic triple-negative breast cancer patients not eligible for PD-1/PD-L1 therapy. Heat and schools: A Europe-wide heatwave is forcing schools to close or shorten days, with limited cooling in many classrooms raising concerns for child health. Travel health rules: UK authorities warn holidaymakers returning from the EU not to bring banned meat and dairy items to avoid fines and confiscation.

Rett syndrome treatment: The EU’s CHMP has issued a positive opinion for Acadia’s DAYBU (trofinetide) for neurobehavioral symptoms of Rett syndrome in adults and children aged 5+, with European Commission approval still expected. The recommendation is based on the Phase 3 LAVENDER study showing improvements on key symptom measures. Bladder cancer care: The European Commission approved Merck/MSD’s perioperative KEYTRUDA (pembrolizumab) plus Padcev (enfortumab vedotin) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, including treatment before and after surgery. Breast cancer option: Gilead’s Trodelvy (sacituzumab govitecan) won EU marketing authorization as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 therapy. Heat and schools: A Europe-wide heatwave is forcing schools to close or shorten days, with limited cooling and health risks for children. Travel health & safety: UK airport guidance warns travellers returning from the EU that several meat and dairy items are illegal in Great Britain and can be seized.

Rett syndrome breakthrough (EU): Acadia’s DAYBU® (trofinetide) won a positive CHMP recommendation for approval in the EU to treat neurobehavioral symptoms of Rett syndrome in adults and children aged 5+. If the European Commission follows, it would be the first EU therapy for this specific indication, based mainly on the Phase 3 LAVENDER study showing improvements on key symptom scales. Bladder cancer care (EU): Merck/MSD’s Keytruda® plus Padcev® secured EU approval for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, using a perioperative approach (before and after surgery) and reporting major gains in event-free survival and pathologic complete response. Breast cancer option (EU): Gilead’s Trodelvy® (sacituzumab govitecan) was approved by the European Commission as first-line monotherapy for certain adults with unresectable or metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitor therapy. Heat and schools (Europe): A record heatwave is forcing schools to close or shorten days across parts of Europe, with limited cooling options leaving classrooms struggling to protect children. Travel health reminder (UK/EU): Luton Airport warned holidaymakers returning to Great Britain that some meat and dairy items from the EU are illegal to bring back, with confiscation and possible fines.

Cancer Care in Europe: The European Commission has approved Merck/MSD’s KEYTRUDA plus Padcev (pembrolizumab + enfortumab vedotin) for perioperative treatment of cisplatin-ineligible, resectable muscle-invasive bladder cancer—neoadjuvant before surgery and continued after radical cystectomy—based on KEYNOTE-905/EV-303 results showing major drops in recurrence and death risk. Breast Cancer Option: Gilead’s Trodelvy (sacituzumab govitecan) also won EC approval as first-line monotherapy for unresectable or metastatic triple-negative breast cancer in patients who can’t use PD-1/PD-L1 therapy, marking a first antibody-drug conjugate option for this setting in the EU (including Liechtenstein). Heat and Schools: A Europe-wide heatwave is forcing schools to close or shorten days, with limited air-conditioning leaving classrooms dangerously hot. Immigration & Health Policy Tension: Swiss political debate continues over measures affecting foreign residents, including proposals that could clash with free-movement rules—an issue that may indirectly shape access to work and services.

Travel Health & Safety: UK’s Luton Airport warns holidaymakers returning to Great Britain not to pack certain meat and dairy “souvenirs,” citing rules meant to prevent spread of animal diseases like Foot and Mouth. Cancer Care (EU/Liechtenstein): The European Commission approved Gilead’s Trodelvy for first-line metastatic triple-negative breast cancer in patients not eligible for PD-1/PD-L1 therapy, and approved Merck/MSD’s Keytruda plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer, including perioperative use and continued treatment after surgery. Heat in Schools: A Europe-wide heatwave is forcing schools to close or shorten days, with classrooms lacking cooling and children struggling as temperatures soar. Disability Benefits Abroad (UK): PIP claimants are reminded to contact the DWP if travel abroad will last more than four weeks, or payments could be affected. Immigration & Permits (Basel): A Basel immigration official faces trial over alleged wrongful permit denials affecting hundreds of EU citizens.

Cancer Care in Europe: The European Commission has approved Gilead’s Trodelvy (sacituzumab govitecan) as a first-line option for metastatic triple-negative breast cancer patients who can’t use PD-1/PD-L1 inhibitors, including in Liechtenstein. Bladder Cancer Update: MSD’s Keytruda plus Padcev (pembrolizumab + enfortumab vedotin) also received EC approval for cisplatin-ineligible muscle-invasive bladder cancer, as a perioperative treatment and continued after surgery across the EU plus Liechtenstein. Heat and Health at School: Record heat is forcing schools across Europe to close or shorten days, with limited cooling and reports of students collapsing in classrooms—raising concerns about child protection during extreme temperatures. Immigration Policy Watch: Switzerland’s parliament is debating new “foreigner” fees and taxes tied to security and infrastructure costs, with potential knock-on effects for EU/EFTA residents, including Liechtenstein citizens. Access to Care & Travel Rules: Summer holiday travel can affect disability benefits in the UK if PIP claimants are abroad too long, with guidance urging people to report trips over four weeks.

Cancer Care in Europe: The European Commission approved perioperative and adjuvant pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) for adults with resectable muscle-invasive bladder cancer who can’t receive cisplatin, with results from the KEYNOTE-905/EV-303 trial showing a 60% lower risk of event-free survival events versus surgery alone; the approval also covers subcutaneous Keytruda and applies across EU plus Iceland, Liechtenstein, and Norway. Breast Cancer Option: Trodelvy (sacituzumab govitecan) won first-line approval in the EU for metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 inhibitor therapy, positioning it as a new early treatment choice for a hard-to-treat group. Health Policy & Access: Liechtenstein’s Crown Prince Alois says he would veto a popular initiative to decriminalize early-pregnancy abortion, arguing time limits don’t sufficiently protect life and favoring a medical-indications, criminal-law framework. Patient Travel Rules: UK PIP claimants are being warned that summer trips abroad can affect payments—notify the DWP if travel will be longer than four weeks, with continued eligibility typically up to 13 weeks (or longer for medical treatment). EU Consumer Safety Law: The revised EU Product Liability Directive is moving toward a December 2026 national-law deadline, with early drafts suggesting different interpretations and potentially higher litigation exposure for digital and software-related products.

Cancer Care in Europe: The European Commission approved perioperative pembrolizumab (Keytruda) plus enfortumab vedotin (Padcev) for adults with resectable muscle-invasive bladder cancer who can’t have cisplatin, with treatment before surgery and continued after radical cystectomy—covering Liechtenstein and other EEA countries. Breast Cancer Update: Trodelvy (sacituzumab govitecan) also won EU approval as a first-line option for unresectable or metastatic triple-negative breast cancer patients who are not candidates for PD-1/PD-L1 therapy, including Liechtenstein. Health Policy & Access: A Liechtenstein-related political move is in the spotlight as Crown Prince Alois says he would veto a popular initiative to decriminalize early-pregnancy abortion, keeping a criminal-law framework with medical indications. Digital Health & Compliance: A new EU-wide onboarding approach aims to link identity checks directly to Qualified Electronic Signatures, reducing gaps that can break the legal chain. Public Health Safety Net: UK guidance warns PIP recipients that going abroad for more than four weeks can affect eligibility, with longer stays allowed only under specific conditions.